H.E. Gall
Impact in
- Oncology top 10%
- Cancer Treatment and Pharmacology
- Metal complexes synthesis and properties
- Colorectal Cancer Treatments and Studies
- Pathology and Forensic Medicine top 10%
- Chemotherapy-induced organ toxicity mitigation
Papers in
- Oncology 14
- Metal complexes synthesis and properties 5
- Cancer Immunotherapy and Biomarkers 4
- Cancer Treatment and Pharmacology 2
-
- Chemotherapy-induced organ toxicity mitigation 10
- Co-authors
- Herbert M. Pinedo (8 shared papers)I. Klein (6 shared papers)Epic Boven (2 shared papers)Wim J.F. van der Vijgh (5 shared papers)Jan Baptist Vermorken (4 shared papers)Albert LEYVA (2 shared papers)Paul A. Maessen (1 shared paper)Klaus B. Mross (1 shared paper)
- Journals
- British Journal of Cancer (2 papers)Human Genetics (1 paper)Journal of Clinical Oncology (1 paper)Annals of Oncology (1 paper)European Urology (1 paper)
- Partner nations
- NetherlandsGermanyBelgium
In The Last Decade
H.E. Gall
28 papers receiving 878 citations
Peers
Comparison fields: 5 of 93
- Oncology 373
- Pathology and Forensic Medicine 148
- Hematology 61
- Molecular Biology 284
- Immunology 84
Countries citing papers authored by H.E. Gall
This map shows the geographic impact of H.E. Gall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.E. Gall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.E. Gall more than expected).
Fields of papers citing papers by H.E. Gall
This network shows the impact of papers produced by H.E. Gall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.E. Gall. The network helps show where H.E. Gall may publish in the future.
Co-authors
The 25 scholars most cited alongside H.E. Gall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1988 | 165 | |
| 2 | Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. | 1984 | 114 |
| 3 | Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. | 1986 | 107 |
| 4 | Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. | 1984 | 77 |
| 5 | 1982 | 68 | |
| 6 | Pharmacokinetics of carboplatin after i.v. administration. | 1987 | 63 |
| 7 | 2000 | 55 | |
| 8 | Phänologische Entwicklungsstadien der Kartoffel (Solanum tuberosum L.) | 1993 | 46 |
| 9 | 2003 | 45 | |
| 10 | Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. | 1999 | 41 |
| 11 | Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. | 1998 | 27 |
| 12 | 2002 | 23 | |
| 13 | 1994 | 22 | |
| 14 | 1989 | 17 | |
| 15 | Delayed-type hypersensitivity reactions to tumor-associated antigens in colon carcinoma patients immunized with an autologous tumor cell/Bacillus Calmette-Guérin vaccine. | 1993 | 15 |
| 16 | 1981 | 12 | |
| 17 | 1994 | 10 | |
| 18 | Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue. | 1986 | 7 |
| 19 | 1988 | 6 | |
| 20 | 1997 | 4 |
About H.E. Gall
H.E. Gall is a scholar working on Oncology, Pathology and Forensic Medicine, Immunology, Pediatrics, Perinatology and Child Health and Hematology, having authored 28 papers that have together received 938 indexed citations. Recurring topics across this work include Chemotherapy-induced organ toxicity mitigation (10 papers), Metal complexes synthesis and properties (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Lanthanide and Transition Metal Complexes (4 papers), Biochemical and Molecular Research (2 papers), Colorectal and Anal Carcinomas (2 papers), HIV/AIDS drug development and treatment (2 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Oncology (373 citations), Pathology and Forensic Medicine (148 citations), Hematology (61 citations), Molecular Biology (284 citations) and Immunology (84 citations). H.E. Gall has collaborated with scholars based in Netherlands, Germany and Belgium. Frequent co-authors include Herbert M. Pinedo, I. Klein, Epic Boven, Wim J.F. van der Vijgh, Jan Baptist Vermorken, Albert LEYVA, Paul A. Maessen, Klaus B. Mross, W J van der Vijgh and C.J. van Groeningen. Their work appears in journals such as British Journal of Cancer, Human Genetics, Journal of Clinical Oncology, Annals of Oncology and European Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.